As filed with the Securities and Exchange Commission on March 29, 2016
Registration No:333-03895
333-95129
333-95127
333-91386
333-134608
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
Post-Effective Amendment No. 1 to Registration Statement No. 333-03895
Post-Effective Amendment No. 2 to Registration Statement No. 333-95129
Post-Effective Amendment No. 1 to Registration Statement No. 333-95127
Post-Effective Amendment No. 2 to Registration Statement No. 333-91386
Post-Effective Amendment No. 2 to Registration Statement No. 333-134608
UNDER
THE SECURITIES ACT OF 1933
Pathfinder Cell Therapy, Inc.
(Exact name of Registrant as specified in its charter)
| Delaware | 14-1745197 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer identification No.) |
12 Bow Street
Cambridge, Massachusetts 02138
(Address of principal executive offices and Zip Code)
(617) 245-0849
(Registrant's telephone number, including area code)
2006 STOCK OPTION PLAN
2001 NONQUALIFIED STOCK OPTION PLAN
2000 NONQUALIFIED STOCK OPTION PLAN
1992 STOCK OPTION PLAN
CERTAIN NON-PLAN STOCK OPTIONS
(full title of plans)
Richard L. Franklin, M.D., Ph.D.
12 Bow Street
Cambridge, Massachusetts 02138
(617) 245-0289
(Name, address, and telephone number of agent for service)
With a copy to:
Keith M. Moskowitz, Esq.
Eilenberg & Krause LLP
11 East 44th Street
New York, New York 10017
Tel. (212) 986-9700
Fax (212) 986-2399
EXPLANATORY NOTE
Pathfinder Cell Therapy, Inc. (the “Company”) is hereby filing this Post-Effective Amendment to each of its Registration Statements on Form S-8(registration nos. 333-03895; 333-95129, 333-9512, 333-91386, 333-134608) (collectively, the “Registration Statements”)to remove from registration all securities of the Company that remain unsold under the Registration Statements.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has duly caused this Post-Effective Amendment to its Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on March 29, 2016.
| PATHFINDER CELL THERAPY, INC. | ||
| By: | /s/ Richard L. Franklin, M.D., Ph.D. | |
| Richard L. Franklin, M.D., Ph.D. Chief Executive Officer and President | ||
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment to the Registration Statements on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated:
| Signature | Title | Date | ||
/s/ Richard L. Franklin, M.D., Ph.D. | Chief Executive Officer, President and Director | March 29, 2016 | ||
| Richard L. Franklin, M.D., Ph.D. | (Principal Executive Officer) | |||
/s/ John Benson | Chief Financial Officer | March 29, 2016 | ||
| John Benson | (Principal Financial and Accounting Officer) | |||
/s/ Joerg Gruber | Chairman of the Board of Directors | March 29, 2016 | ||
| Joerg Gruber | ||||
/s/ John L. Brooks III | Director | March 29, 2016 | ||
| John L. Brooks III | ||||
/s/ Zen Chu | Director | March 29, 2016 | ||
| Zen Chu | ||||
/s/ John Alam, M.D. | Director | March 29, 2016 | ||
| John Alam, M.D. | ||||
/s/ Brock Reeve | Director | March 29, 2016 | ||
| Brock Reeve |